22nd Century to Present Overview of Company’s Medical Marijuana & Industrial Hemp Initiatives at LD Micro Investor Conference
December 05 2016 - 10:00AM
Business Wire
“Research is opening exciting new paths to
medically-important and industrially-important products.”
22nd Century Group, Inc. (NYSE MKT: XXII), a leader in tobacco
harm reduction and cannabis research, announced today that the
Company will present at the LD Micro Invitational Investor
Conference at the Luxe Sunset Boulevard Hotel, 11461 Sunset
Boulevard, Los Angeles, California, on Wednesday, December 7, 2016
at 1:30 p.m. EST.
Henry Sicignano, III, President and Chief Executive Officer, and
Dr. Paul Rushton, Vice President of Plant Biotechnology, will
provide investor attendees with a business update and will
highlight 22nd Century’s advances in the rapidly evolving legal
medical marijuana and industrial hemp markets. Headlining the
presentation will be Dr. Rushton’s discussion of the Company’s
proprietary cannabis initiatives, including the development of
THC-free industrial hemp varieties and the propagation of medical
marijuana strains that are selected for increased levels of
medically-important cannabinoids, such as CBC and CBD. Both Mr.
Sicignano and Dr. Rushton will be available for one-on-one meetings
at the conference.
Dr. Rushton explained, “We are delighted that our research and
development is opening exciting new paths to medically-important
and industrially-important products. We are developing new medical
marijuana as well as industrial hemp varieties with substantially
altered levels of cannabinoids, all of which will be below the
legal limit of 0.3% THC. We aim to become major suppliers of
proprietary plants for both legal medical marijuana and industrial
hemp cultivation, which are projected to be multi-billion dollar
markets in the near term. The Company is actively filing
provisional patents in these fields. We are also expanding our
activities in an increasing number of pilot hemp projects with
research universities possessing all necessary federal and state
licenses and permits. These are exciting times indeed.”
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company focused on
technology which allows it to increase or decrease the level of
nicotine in tobacco plants and the level of cannabinoids in
cannabis plants through genetic engineering and plant breeding. The
Company’s primary mission is to reduce the harm caused by smoking.
22nd Century currently owns or exclusively controls more than 200
issued patents and more than 50 pending patent applications around
the world. For more information, visit www.xxiicentury.com and
www.botanicalgenetics.com.
Cautionary Note Regarding Forward-Looking Statements: This press
release contains forward-looking information, including all
statements that are not statements of historical fact regarding the
intent, belief or current expectations of 22nd Century Group, Inc.,
its directors or its officers with respect to the contents of this
press release, including but not limited to our future revenue
expectations. The words “may,” “would,” “will,” “expect,”
“estimate,” “anticipate,” “believe,” “intend” and similar
expressions and variations thereof are intended to identify
forward-looking statements. We cannot guarantee future results,
levels of activity or performance. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the United States, we do not
intend to update any of the forward-looking statements to conform
these statements to reflect actual results, later events or
circumstances, or to reflect the occurrence of unanticipated
events. You should carefully review and consider the various
disclosures made by us in our annual report on Form 10-K for the
fiscal year ended December 31, 2015, filed on February 18, 2016,
including the section entitled “Risk Factors,” and our other
reports filed with the U.S. Securities and Exchange Commission
which attempt to advise interested parties of the risks and factors
that may affect our business, financial condition, results of
operation and cash flows. If one or more of these risks or
uncertainties materialize, or if the underlying assumptions prove
incorrect, our actual results may vary materially from those
expected or projected.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161205005772/en/
Investor Relations:IRTH CommunicationsAndrew Haag,
866-976-4784xxii@irthcommunications.comorRedington, Inc.Tom
Redington, 203-222-7399
22nd Century (AMEX:XXII)
Historical Stock Chart
From Aug 2024 to Sep 2024
22nd Century (AMEX:XXII)
Historical Stock Chart
From Sep 2023 to Sep 2024